Association between the FOXP2 immunostaining (IHC) result and prostate cancer phenotype
| Parameter | n Evaluable | FOXP2 IHC result | p Value | |||
|---|---|---|---|---|---|---|
| Negative (%) | Weak (%) | Moderate (%) | Strong (%) | |||
| All cancers | 8.289 | 6 | 19 | 34 | 41 | |
| Tumour stage | ||||||
| pT2 | 5.546 | 7 | 21 | 34 | 38 | <0.0001 |
| pT3a | 1.796 | 5 | 16 | 33 | 46 | |
| pT3b | 904 | 3 | 14 | 40 | 43 | |
| pT4 | 22 | 0 | 5 | 45 | 50 | |
| Gleason grade | ||||||
| <3+3 | 1.817 | 8 | 23 | 35 | 34 | <0.0001 |
| 3+4 | 4.827 | 6 | 19 | 33 | 42 | |
| 4+3 | 1.220 | 4 | 16 | 36 | 45 | |
| >4+4 | 394 | 3 | 13 | 40 | 44 | |
| Lymph node metastasis | ||||||
| N0 | 4.363 | 6 | 18 | 34 | 43 | <0.0001 |
| N+ | 429 | 4 | 10 | 40 | 46 | |
| Surgical margin | ||||||
| Negative | 6.652 | 6 | 19 | 34 | 41 | 0.2967 |
| Positive | 1.479 | 6 | 17 | 38 | 46 | |